Hämäläinen Iiro, Törnwall Outi, Simell Birgit, Zatloukal Kurt, Perola Markus, van Ommen Gert-Jan B
1 Institute for Molecular Medicine, Finland (FIMM), and Diabetes and Obesity Research Program, University of Helsinki, Helsinki, Finland.
2 Department of Public Health Solutions, National Institute for Health and Welfare, Helsinki, Finland.
Biopreserv Biobank. 2019;17(1):46-51. doi: 10.1089/bio.2018.0024. Epub 2018 Nov 30.
Public-private partnerships (PPP) are an efficient means to advance scientific discoveries and boost the medical innovations needed to improve precision medicine. The increasing number and novel nature of such collaborations is keeping the biomedical field in constant flux. Here we provide an update on PPP development involving academic biobanks in the BBMRI community (the European Biobanking and BioMolecular Resources Research Infrastructure) and report the views on PPP of 20 key players from this field. The interviewed academic representants broadly show interest for their institution to establish PPP and initiate or partner with BBMRI expert centers. The results indicate that PPP has gained foothold in this area of biomedical research, with great promise to facilitate access to samples and data and to improve data interoperability and reproducibility.
公私合作伙伴关系(PPP)是推动科学发现以及促进精准医学所需医学创新的有效手段。此类合作数量的不断增加及其新颖性使生物医学领域持续处于变化之中。在此,我们提供有关BBMRI社区(欧洲生物样本库与生物分子资源研究基础设施)中学术生物样本库公私合作伙伴关系发展的最新情况,并报告该领域20位关键参与者对公私合作伙伴关系的看法。接受采访的学术代表普遍表示,他们所在的机构有兴趣建立公私合作伙伴关系,并与BBMRI专家中心开展合作或建立伙伴关系。结果表明,公私合作伙伴关系已在这一生物医学研究领域站稳脚跟,有望促进样本和数据的获取,并提高数据的互操作性和可重复性。